| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003 and expected initiation of Phase 1 clinical trial |
| 09 Jun 2026 |
8-K: Other Events
Registration Statement on Form S-3 Enveric Biosciences, Inc. |
| 09 Jun 2026 |
8-K: Regulation FD Disclosure
Enveric Biosciences, Inc. (the “Company”) has prepared presentation materials (the “Investor Presentation”) that management intends to release on its website on or about June 8, 2026. From time to time thereafter, the Company may use the... |
| 29 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
1. Award of Restricted Stock Units. Pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the “Plan”) for Employees, Contractors, and Outside Directors of Enveric Biosciences, Inc., a Delaware corporation (the “Company... |
| 15 May 2026 |
8-K: Results of Operations and Financial Condition
Continued advancement of lead candidate EB-003 with IND-enabling studies progressing toward planned first-in-human clinical trial |
| 30 Apr 2026 |
8-K: Other Events
We are writing to inform you of an important update regarding our 2026 Annual Meeting of Stockholders. After the distribution of our definitive proxy statement, dated April 14, 2026, we identified a typographical error. |
| 20 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
This Securities Purchase Agreement (this “Agreement”) is dated as of April 16, 2026, between Enveric Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including ... |
| 27 Mar 2026 |
8-K: Results of Operations and Financial Condition
Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements in animal models of severe chronic depression and despair and in post-traumatic stress disorder (PTSD) |
| 06 Feb 2026 |
8-K: Other Events
Registration Statement on Form S-3 Enveric Biosciences, Inc. |
| 28 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This Securities Purchase Agreement (this “Agreement”) is dated as of January 27, 2026, between Enveric Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, includin... |
| 09 Jan 2026 |
8-K: Regulation FD Disclosure
Enveric Biosciences, Inc. (the “Company”) has prepared presentation materials (the “Investor Presentation”) that management intends to release on its website on or about January 9, 2026. From time to time thereafter, the Company may use ... |
| 12 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UN... |
| 11 Dec 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On December 11, 2025, Enveric Biosciences, Inc. (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). A total of 2,502,133 shares of the Company’s common stock were present in person or represented by proxy at t... |
| 14 Nov 2025 |
8-K: Other Events
On November 12, 2025, Enveric Biosciences, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the ... |
| 14 Nov 2025 |
8-K: Results of Operations and Financial Condition
In Q3, Enveric continued toward clinical readiness for lead candidate EB-003, targeting neuropsychiatric indications, announcing additional positive data in a preclinical model of PTSD, successful completion of dose range finding studies... |
| 23 Oct 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Material Modification to Rights of Security Holders +2 more
Common Stock Will Begin Trading on a Split-Adjusted Basis on October 28, 2025 |
| 18 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UN... |
| 02 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
Move aligns with company’s vision to leverage the Greater Boston biotech hub’s scientific and financial ecosystem and advance EB-003 into first-in-human trial in 2026 |
| 29 Aug 2025 |
8-K: Regulation FD Disclosure
Enveric Biosciences, Inc. (the “Company”) has prepared presentation materials (the “Investor Presentation”) that management intends to release on its website on or about August 29, 2025. From time to time thereafter, the Company may use ... |
Loading...